Leap Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Leap Therapeutics to participate in two investor conferences

Positive

• Leap Therapeutics, Inc. will be participating in the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023, and the Baird Global Healthcare Conference on September 13th, 2023. The company's President and CEO, Douglas E. Onsi, will be presenting at these conferences. Investors can access a replay of the H.C. Wainwright presentation and a live webcast of the Baird fireside chat on the company's website.

Negative

• None.

CAMBRIDGE, Mass., Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming investor conferences:

Leap Presentation Details:

H.C. Wainwright 25^th Annual Global Investment Conference
Date: Monday, September 11^th, 2023
Time: 7:00 a.m. Eastern Time

Baird Global Healthcare Conference
Date: Wednesday, September 13^th, 2023
Time: 3:10 p.m. Eastern Time

A replay of the pre-recorded H.C. Wainwright presentation and a live webcast of the Baird fireside chat may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the events will also be available for a limited time.

About Leap Therapeutics

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com

Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
matthew@argotpartners.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-upcoming-investor-conferences-301917374.html

SOURCE Leap Therapeutics, Inc.

FAQ

When will Leap Therapeutics be participating in investor conferences?

Leap Therapeutics will be participating in the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023, and the Baird Global Healthcare Conference on September 13th, 2023.

Who will be presenting at the conferences?

Douglas E. Onsi, the President and CEO of Leap Therapeutics, will be presenting at the conferences.

Where can investors access the presentations?

Investors can access a replay of the H.C. Wainwright presentation and a live webcast of the Baird fireside chat on the Investors page of Leap Therapeutics' website.

Will there be a replay available for the events?

Yes, a replay of the events will be available on Leap Therapeutics' website for a limited time.